Affordable Access

deepdyve-link
Publisher Website

Adverse Drug Reaction Reporting and Prescribing Trends of Drugs for Attention Deficit Hyperactivity Disorder in Primary Care England, 2010-2019.

Authors
  • Hasan, Syed Shahzad1
  • Bal, Nimrata1
  • Baker, Isabelle1
  • Kow, Chia Siang2
  • Khan, Muhammad Umair3
  • 1 University of Huddersfield, UK.
  • 2 International Medical University, Kuala Lumpur, Malaysia. , (Malaysia)
  • 3 Ziauddin University, Karachi, Pakistan. , (Pakistan)
Type
Published Article
Journal
Journal of Attention Disorders
Publisher
SAGE Publications
Publication Date
Feb 01, 2022
Volume
26
Issue
3
Pages
467–475
Identifiers
DOI: 10.1177/1087054721997556
PMID: 33666114
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

We investigated the prescription trends and adverse drug reactions (ADRs) of ADHD drugs in primary care, England between 2010 and 2019. The Prescription Cost Analysis database presenting the primary care prescriptions data and the Interactive Drug Analysis Profiles presenting all suspected ADRs reported for each drug were screened. The data were analyzed using linear regression analysis to examine the annual average change per year. The prescription items dispensed for ADHD showed an average 11.07% (95% CI 10.54-11.60, p = .001) increase per year and there was a mean 11.54% (95% CI 11.03-12.06, p = .001) increase per year in the costs. The overall reporting of serious and fatal ADR was reduced by 1.79% per year for ADHD drugs. Guanfacine showed a 40% mean increase per year. The increasing use of ADHD drugs within primary care in England could be a result of multiple factors such as growing ADHD prevalence.

Report this publication

Statistics

Seen <100 times